RNAZ RNAZ
Company Profile ↓Company Overview
RNAZ (RNAZ) is a publicly traded company listed on with a market capitalization of $3.90M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.00.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -63.04% |
| 6 Months: | -52.67% |
| 3 Months: | -45.93% |
| 1 Month: | -49.64% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)33.11 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 72.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.82M | 4.07M | 4.54M | 6.49M | 17.62M |
| Operating Income | - | -91.61K | -239.49K | -449.46K | -355.53K | -2.36M | -3.48M | -4.71M | -4.95M | -4.89M | -5.12M | -5.31M | -3.29M | -5.11M | -2.17M | -2.82M | -4.07M | -4.54M | -6.49M | -17.62M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.03M | -4.26M | -4.85M | -13.17M | -17.53M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 114 | 0 | 5.96K | 542 | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.09M | -4.28M | -4.86M | -13.22M | -17.55M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 231.31K |
| Net Income | -41.26K | -127.20K | -1.37M | -4.49M | 2.77M | -2.33M | -3.47M | -4.67M | -4.29M | -4.82M | -4.34M | -5.30M | -3.33M | -5.19M | -2.32M | -12.09M | -4.28M | -4.86M | -13.44M | -17.79M |
| Diluted EPS | - | -0.03 | - | -0.97 | 0.51 | -0.20 | -0.27 | -7.20 | -6.61 | -259.07 | -142.38 | -48.44 | -21.35 | -680.23 | -146.06 | -70.16 | -5.13 | -5.82 | - | -21.28 |
| R&D Expense | - | 75.00K | 53.94K | 263.76K | 211.75K | 992.95K | 1.88M | 2.62M | 3.04M | 2.59M | 2.97M | 3.34M | 1.76M | 3.08M | 1.23M | 2.22M | 2.57M | 3.16M | - | 5.11M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 17.55M | 18.50M | 15.14M | 17.92M |
| Operating Income | -726.60K | - | -17.55M | -18.50M | -15.14M | -17.92M |
| EBITDA | - | - | -17.43M | -17.97M | -16.19M | -34.31M |
| Interest Expense | - | - | 31.99K | 55.90K | 26.81K | 6.62K |
| Pretax Income | - | - | -17.56M | -18.55M | -16.75M | -34.44M |
| Tax Provision | - | - | - | - | 0 | 226.07K |
| Net Income | -2.34M | - | -17.56M | -18.55M | -16.75M | -34.66M |
| Diluted EPS | -0.51 | - | -1,033,233.41 | -27,313.84 | -1,336.63 | -52.59 |
| R&D Expense | 284.46K | 2.75M | 10.23M | 12.26M | 9.71M | 13.42M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.06M | - | 7.59M | 5.17M | 7.29M | 162.40M |
| Current Assets | - | - | - | 7.38M | 4.46M | 7.09M | 21.98M |
| Cash & Equivalents | - | 828.02K | - | 4.97M | 2.77M | 5.81M | 17.81M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 360.23K | 0 | 0 | 953.10K |
| Total Liabilities | - | 4.46M | - | 4.35M | 3.53M | 9.31M | 10.52M |
| Current Liabilities | - | 404.86K | - | 4.35M | 3.49M | 2.77M | 3.49M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 0 | 450.57K | 38.29K | 0 |
| Total Equity | -1.11M | -3.41M | - | 3.24M | 1.64M | -2.02M | 151.88M |
| Shares Outstanding | - | - | - | 17 | 679 | 36.75K | 916.97K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -492.97K | - | -15.76M | -18.07M | -13.34M | -19.52M |
| Investing Cash Flow | - | - | -100.92K | -35.61K | -21.76K | -4.44K |
| Financing Cash Flow | 1.12M | - | 5.99K | 15.91M | 16.40M | 31.52M |
| Capital Expenditure | - | - | -100.92K | -35.61K | -21.76K | -6.66K |
| Free Cash Flow | - | - | -15.86M | -18.11M | -13.36M | -19.52M |
| Net Change in Cash | - | - | -15.86M | -2.20M | 3.04M | 12.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 68.8% | - | -542.0% | -1,130.3% | 830.0% | -22.8% |
| ROCE % | -111.7% | - | -541.7% | -1,101.5% | -334.7% | -11.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RNAZ
DEFJ lifts TransCode Therapeutics (RNAZ) stake to 83.9% after conversions - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQWjNTU2RJenFncTZMclR5ejRqVHpsaGZjbHF6bjhrLVZNRWFnU2FaYWMxbm13dWV3RE9LZkRMRkJHVkQ2cmotWnFKT2x6cnNLbEQ2R2ZXcFVYS25TOENOTWlFLUNwNHZxVlh4WmVDeDVkRTY3UXo3TWQ0QklvTGtFQ3dCVUM2TndzTHNFd1…
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOMnd4M3ZxdkFMZUo2SjJ4OFR3R3ZybDNEcG0tRS00YWNVQkROaXVMLTBLQUR2Tmh3SnYyd01QcnZqS1pqVXZsUUxzaWxZVjFiME9YZHJtUGhKdUZvcGpzbXhrRDBLc1I3dWdyWXh0UXFIYW8wVE9tWjktOUR0b3ZleXdvMWwyNlhNOHpwT0…
RNAZ | TransCode Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTFA5WHRKejRLTXpzMU1Ia0pUalMwUktac0lVS0ExVC1ZYzBvWjQ4Slc3WktFZDQ4cUo2UU1COTVxblRva1NaTG5tWF9pTnVMWUIwYUpRbVBDMC1vNXNS?oc=5" target="_blank">RNAZ | TransCode Therapeutics, Inc. Common …
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of - PR Newswire
<a href="https://news.google.com/rss/articles/CBMilgNBVV95cUxNWE1kQ28wMGt6QnE2RHNROVJjZmNlaU8tZzM3YVdZc1ctWVVCTEdqSnZsZ3dqQ3k3NU1YLWRyakJ0NVZaZmVXbXl3clJYcVN4RkRaX28xOEJIN1ZjLXcyVEV6Z1ExZWxLaVBtNElKVDRDWXhRYldrcG1TNTR2UFNKVm5rT1FWX0ljdXhxWV…
TransCode Therapeutics (RNAZ) AGM 2026 Summary - Quartr
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxQUzdjSEYtMHhlRnZWNTU4RlhvMGNJVkxFejlWWVEtcGVYSHBIZk81RFdnSHJqTTB6UVh3M2g5eVc0aHpHRFFYaTlndmRXa3ZvanktY3VBdGJTMDdfaDRKbG9xaUx0YUFiU0J2QUl2MjdCWElaQ25FR1l1cUpoZEZiNA?oc=5" target="_…
TransCode Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNAZ - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE1qcGh0TEk4Z0o3YWt3dXQ5cEVYWTJONU1PeGdrc2FaMTdDZS1RenpSeFNCMWc3dGpXR0ZURkV2OTZ0bXhUY28wMTVwRjFESm1VRmd4Q2xVOG16OG04M2x4WWozU3ZKUk50aXpic09mNmFXS2o2QmFv?oc=5" target="_blank">TransCo…
RNAZ — Frequently Asked Questions
What is the current share price of RNAZ?
As of 2026-08-05 17:25 PDT, RNAZ trades at $4.25 on NASDAQ/NYSE. Its 52-week range is $4.22 to $15.23.
What is the market capitalisation of RNAZ?
RNAZ has a market capitalisation of $3.90M on NASDAQ/NYSE.
What is the P/E ratio of RNAZ?
RNAZ trades at a trailing price-to-earnings (P/E) ratio of -0.08. Its price-to-book (P/B) ratio is 0.03.
What is the return on equity (ROE) of RNAZ?
RNAZ has a return on equity (ROE) of -22.82%. Its return on capital employed (ROCE) is -11.27%.
Is RNAZ a good stock to buy?
This page provides a data-driven analysis of RNAZ, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.